In this report, we describe our experience with 2 patients who experienced breast implant-associated ALCL. A literature review was performed to examine additional cases and provide greater understanding of this disease.
CASE PRESEntAtionS

Case 1
In June 2011, a 38-year-old woman presented to a private family medicine clinic in Snellville, Georgia, with a 6-week history of right breast swelling. Nine years earlier, she had undergone bilateral submuscular breast augmentation with 510-cc textured saline Biocell implants (Allergan, Inc, Irvine, CA). She had no postoperative complications or previous trauma to the breast, nor did she undergo any additional breast surgery before presentation to the clinic. Her medical history revealed a recent diagnosis of celiac disease, confirmed by duodenal biopsy. Her family history of breast cancer was extensive and included her mother and grandmother. Clinical examination showed swelling and erythema of the right breast, but there were no palpable masses, peau d'orange, or nipple retraction.
A mammogram revealed fluid surrounding an intact right saline implant (Figure 1 ). Ultrasonography confirmed a fluid collection adjacent to the implant that was indicative of an inflammatory process or seroma ( expressed CD2, CD5, CD4, and CD30 and failed to express CD3 or CD7. Results of immunohistochemical staining with hematoxylin and eosin were negative for anaplastic lymphoma kinase 1 (ALK-l). The diagnosis was ALK -ALCL ( Figure 3) .
The patient subsequently underwent magnetic resonance imaging of the breasts, which showed intact implants with posterior fluid collections bilaterally. She was referred to the Hematology and Medical Oncology Department at Winship Cancer Institute (Atlanta, GA) for staging and treatment of ALCL. Results of positron emission tomography scan, bone marrow aspirate, and biopsy were determined to be negative for disease, and her level of lactate dehydrogenase was normal. Treatment included bilateral total capsulectomy and implant removal, without implant replacement in December 2011. After removal, the implants and capsules were sent for flow cytometry and cytogenetic analysis. Immunohistochemical staining did not show any unique cell populations. There was evidence of silicone in the capsule. Throughout the 20 months of regular follow-up since implant removal and capsulectomy, the patient has had no systemic evidence of the disease as of August 2013.
Case 2
In October 2012, this 31-year-old woman presented to the Center for Plastic and Reconstructive Surgery in Orlando, Florida, with acute enlargement of the right breast ( Figure 4 ). She had undergone bilateral breast augmentation 16 years earlier; 425-cc textured round saline implants were placed subglandularly. The manufacturer of the implants was not known. She did not undergo any additional breast surgery before presentation. She denied recent trauma, redness, or drainage. Clinical examination showed swelling of the right breast but no palpable masses. Ultrasonography showed a fluid collection around the right (intact) breast implant. Breast magnetic resonance imaging confirmed the presence of fluid collection and did not reveal any masses ( Figure 5 ). Ultrasound-guided fluid aspiration showed CD30 + , ALK -ALCL. The cells were positive for CD45, CD5, CD4, but failed to express CD34, CD20, CD68, or CD10.
The patient underwent bilateral capsulectomies and implant removal on December 7, 2012 ( Figure 6 ). Immediately after removal, the implants and capsules were examined for malignancy. Flow cytometry, cytogenetic analysis, and immunohistochemical staining failed to identify any unique cell populations. There was no evidence of silicone in the implant capsule. She was referred to the Hematology and Medical Oncology Department at Florida Hospital Orlando (Orlando, Florida), where a positron emission tomography computed tomography scan showed no evidence of disease. The patient did not receive any additional treatment and was free of disease at her 15-month follow-up visit. She continues to be monitored closely because of chronic pain in the affected breast.
LitERAtuRE REviEw
An extensive literature search was performed via PubMed in March 2013 to identify publications pertaining to ALCL of the breast. The search terms were breast implant anaplastic large cell lymphoma, anaplastic large cell lymphoma breast, ALCL, and breast implant cancer. All cases of ALCL primary breast lymphoma that occurred close to a breast implant were included. From these search criteria, 61 cases published between 1997 and 2013 were identified. 
RESuLtS
In addition to the 2 cases presented here, we identified 31 reports describing a total of 61 patients with ALCL in proximity to saline or silicone gel implants (Table 1) , 1, bringing the overall number of reported cases to 63. Three cases were published as letters to the editor, 6, 11, 35 and 1 case was from a meeting abstract. 24 The patients' ages ranged from 28 to 87 years; the median age at diagnosis was 50 years (mean, 51.2). Age at presentation varied by indication for breast implantation: median age was 43 years for augmentation and 62 years for reconstruction. The median time from implant placement to diagnosis of ALCL was 9 years (range, 1-31 years). Implant type was reported for 59 cases, among which the number of silicone and saline implants was nearly identical. Of the 26 cases for which surface texture was documented, 24 (92.3%) had textured implants; the other 2 (7.7%) had polyurethane coating. The implant manufacturer was known in 19 cases (Biocell, n = 14; Nagor [GC Aesthetics, Dublin, Ireland], n = 3; and Poly Implant Prosthèse [PIP; La Seyne-sur-Mer, France], n = 2). The implants were placed for cosmetic purposes in 61.9% of the patients.
ALCL was diagnosed by pathologic examination in all cases. ALK status was available for 57 cases, 56 (98.2%) of which were ALK − ( Table 2 ). The 1 ALK + case was believed to be ALK − from the initial pathologic examination, but subsequent pathologic assessment demonstrated ALK + ALCL. 27 One patient had a history of ALK − ALCL in the supraclavicular and cervical lymph nodes 2 year before the breast diagnosis. 23 One patient had a history of lymphoid papillomatosis of the skin, 5 and 1 had a history of Hodgkin disease 20 years before the ALCL diagnosis. 15 Of the 58 patients with an identifiable presentation, 39 (67.2%) had periprosthetic fluid accumulation, including 7 with an associated mass ( Table 2 ). Thirteen patients (22.4%) presented with an isolated mass, including 1 with associated axillary lymphadenopathy. Information on surgical treatment was available for 56 patients (Table 2) . Forty patients (71.4%) underwent capsulectomy, 7 of whom (12.5%) had the implant replaced. One patient had implant removal alone plus replacement. Information regarding nonsurgical treatment was available for 44 patients (Table 2) . Chemotherapy was administered in 33 patients (75.0), and radiation was used in 23 patients (52.3). Six patients (13.6) were treated by surgery alone.
The availability of survival and long-term follow-up data was inconsistent among the cases. Follow-up time was available for 49 patients, with the median being 18 months (range, 10-24 months). After initial treatment, Table 3 . Of the 18 patients who presented with a mass, 11 (61.1%) had disease recurrence. All 4 patients who died of the disease had presented with a mass. Both patients who initially presented with lymphadenopathy and 2 patients who presented with seroma experienced disease recurrence. Although the latter 2 patients that presented with a seroma were salvaged with systemic chemotherapy, the follow-up period was short.
DiSCuSSion
The apparent increase in reports of ALCL in women with breast implants has become a source of concern for women and physicians worldwide. However, several large epidemiologic studies in Denmark, Sweden, Canada, Finland, and the United States have not demonstrated an association between primary breast lymphoma and breast implants. [36] [37] [38] [39] [40] [41] In an individually matched case-control study of 389 women with primary breast lymphoma, de Jong et al 9 noted an odds ratio of 18.2 (95% confidence interval, 2.1-156.8) for the development of ALCL over other types of lymphoma in the breasts of women with implants. However, the relatively small number of ALCL cases studied (n = 11) limits the power of their analysis. Furthermore, the low incidence of this disease itself, estimated at 0.1 per 100 000 population per year, makes it especially difficult to interpret the association between breast implants and ALCL. 9 Even in long-term epidemiologic studies, the numbers of patients with ALCL and breast implants have been insufficient to determine the absolute risk or true incidence of the disease.
Classification of ALCL
ALCL at all body sites accounts for only 3% of newly diagnosed non-Hodgkin lymphoma. 42 The World Health Organization now recognizes 2 main classifications of ALCL: primary cutaneous ALCL (PC-ALCL) and primary systemic ALCL (PS-ALCL). 43 On one end of the spectrum, PC-ALCL is often manifested only by solitary or localized tumors of the skin without systemic involvement. The prognosis is excellent (5-year survival rate of 90%), and ALK expression is nearly always negative. 44, 45 Skin lesions often regress spontaneously and may recur. They are usually treated with singleagent chemotherapy or radiation. Chronic inflammation of the skin appears to have a role in the development of cutaneous lymphoma. 46 This disease has been associated with insect bites and foreign bodies, such as orthopedic implants, venous access ports, and breast implants. [47] [48] [49] [50] PS-ALCL is clinically aggressive, often with associated B symptoms (fever, night sweats, and weight loss) and extranodal disease at presentation. PS-ALCL has a 5-year survival of 40% and is generally treated with multiagent chemotherapy and radiation. In contrast to PC-ALCL, 60% to 85% of patients with PS-ALCL have ALK + expression. As suggested by Thompson et al 3 and Lechner et al, 20 iALCL may represent a distinct clinicopathologic entity similar to PC-ALCL and distinct from PS-ALCL. Its association with a foreign body (breast implant) and spontaneous remission after removal suggests a reactive component similar to that of PC-ALCL. Patients who experience relapse after multiagent chemotherapy generally have a good prognosis despite their ALK − status, as do patients with PC-ALCL. Kadin et al 51 examined cell lines from iALCL and PC-ALCL and found similar cell morphologies and cytokine profiles.
Etiology and Pathophysiology
Many hypotheses have been proposed to explain the etiology of ALCL in the fluid surrounding breast implants. Many experts agree that chronic inflammation influences the development of ALCL. Some believe that particles from the implant's surface will break off over time, via microtrauma or degradation, leading to an exaggerated immune response. 53 It is possible that this aggregate of T cells in close proximity to silicone could lead to sensitization of T cells to silicone particles or self-proteins, resulting in antigen response and processing. The continual processing of antigens in the chronic inflammatory response could lead to immune dysregulation and, ultimately, lymphoma.
It has also been proposed that macrophages are responsible for initiating ALCL by engulfing particles from the implant's surface. In a study by Wolfram et al 53 of the fibrous capsules of 19 women with breast implants, macrophages were the primary cell type in the capsular layer most adjacent to the implant surface. Prantl et al 54 examined the capsules of 24 women who received cosmetic breast augmentation with smooth silicone gel implants. The macrophages of these capsules were found to have silicone in 16 patients (66.6%). In 13 patients (54.2%), the innermost layer of the capsules contained dissolved, nonstaining silicone that was often surrounded by macrophages and other mononuclear cells. Thicker capsules were associated with a greater silicone burden, and the increase in silicone was associated with larger numbers of inflammatory cells. It is unclear whether the silicone within macrophages originated from the implant surface or from inside the implant. Although silicone was present in the inflammatory cells surrounding the implant, there was no evidence of implant rupture. If the inflammatory response to silicone implants is indeed responsible for the progression to lymphoma, then implant rupture would not be required.
Implant Surface Texture
Due to the apparent association between ALCL and textured Silastic (Dow Corning, Midland, MI) elastomer implants and the lack of association with implant type (saline vs silicone), the inflammatory response may be attributable to the implant cover. Polyurethane coating stimulates a delayed chronic inflammatory process whereby macrophages are recruited to ingest the polyurethane fragments and form microcapsules that prevent capsular contracture. 55 A degradation product of polyurethane was found to be carcinogenic in rats, and polyurethanecoated implants were removed from the market in 1991. 56, 57 Texturing of the Silastic cover was developed in the 1980s to reduce capsular contracture. 58, 59 It is thought that tissue ingrowth into the projections or pores of the textured implant surface prolongs chronic inflammation and results in disorientation of the collagen fibrils. 60 It is noteworthy that 14 of the known textured implants were manufactured with a salt-loss technique that results in very coarse texturing. 61 This may lead to a greater inflammatory response and more antigenic stimulation, as suggested by Lechner et al. 62 Meza Britez et al 63 evaluated the immunophenotype of inflammatory cells of breast implant capsules in 40 women and found that T cells predominated B cells and that the response to T cells was more marked in textured implants than in smooth implants.
Clinical Presentation and Prognosis
Late formation of seroma is the most common presentation of iALCL, associated with two-thirds of the reported cases of iALCL. It is a relatively uncommon complication of breast augmentation, with an incidence of <1%. [64] [65] [66] Most benign late seromas after breast augmentation have occurred with textured implants. [64] [65] [66] [67] [68] In our literature review, all known cases had either a polyurethane or textured silicone surface in some area. Both patients described herein had textured implants.
Aladily et al 5 proposed categorizing the disease into 2 distinct clinicopathologic subgroups based on clinical presentation: with or without gross evidence of a mass. Patients who present with periprosthetic effusion without gross evidence of a mass tend to have a lower risk of disease recurrence. Only 2 patients in our review had disease recurrence, and both were successfully salvaged with systemic therapy. Patients who present with a mass adjacent to the implant tend to have a more aggressive disease course. 5 Of the 18 patients in our review who presented with a mass, 11 (61.1%) had recurrence. Four of these patients died of the disease. The clinical course for this subset of patients more often mimics the systemic form of ALK − ALCL, with variable prognosis and clinical behavior.
Recommendations for Management of iALCL
Kim et al 52 reported results of a structured consultation process that included 10 experts on iALCL, representing the fields of oncology, hematopathology, immunology, and pathology. The conclusions were as follows:
• • There is a positive association between breast implants and development of ALCL, and there is likely underrecognition of the true number of cases. • • Clinically, iALCL is an indolent disease with a favorable prognosis, and it is distinct from PS-ALCL.
• • Management of iALCL should consist of capsulectomy, removal of the involved implant, and evaluation for other sites of involvement. • • Adjuvant radiation and chemotherapy should not be offered to patients with capsule-defined disease.
However, the panel disagreed on the management of the contralateral side and was uncertain of the risk of immediate reimplantation. 52 Thompson et al 3 characterized ALCL that presented as a fluid collection adjacent to breast implants as "effusion-associated ALCL." Yet, reporting on a consensus panel recommendation, Bengtson et al 69 noted that "late periprosthetic fluid collection" would be a more accurate description in light of the lack of standard measures of periprosthetic fluid throughout the literature (eg, cell count, specific gravity, appearance, protein content, glucose level, albumin level). The authors also questioned the subjective definition of "late" being >1 year after implantation. They established an algorithm for percutaneous aspiration of fluid with culture and cell counts. Documentation of periprosthetic fluid collection by ultrasonography was recommended for recurrent or persistent swelling, with referral to hematopathology if malignancy is suspected. 69 In a review of the pathologic and immunohistochemical features of 103 cases, Taylor et al 70 advocated for initial consideration of the iALCL diagnosis, with subsequent confirmation by immunohistochemical staining that includes CD30, ALK, and certain T-cell markers. Given the variable clinical course noted in our review, timely diagnosis to avoid delayed exploration of the capsule and implant removal is important. Until recently, the seroma fluid containing malignant cells may have been discarded without any further analysis, leading to discrepancies in the diagnosis and reporting of these cases. It is possible that simply draining the seroma "cured" the disease in many of these patients, without the physician or patient having being aware of the malignancy.
Neither of our patients had evidence of ALCL at the time of total capsulectomy. No further treatment was provided, and they have remained free of recurrence. Thus, the clinical course of ALCL in women with breast implants may vary depending on whether the presentation is seroma or capsular involvement, even though both scenarios have the same immunohistochemistry, histology, and pathology. This distinction suggests a difference in genetic phenotype and gene expression that has not yet been determined. Nevertheless, the likelihood that the different outcomes result from varying degrees of the same disease is high. Women who present with a mass may have had an unrecognized seroma that resolved spontaneously. Leaving malignant cells in the implant capsule may trigger further mutations, leading to the organization of a periprosthetic mass. Moreover, the long-standing protocol of discarding seroma aspirate may prevent early recognition of the disease and allow for additional mutations within malignant cells, thereby increasing the likelihood of more aggressive disease. These hypotheses require further investigation.
US Food and Drug Administration
In 2013, the FDA released a statement acknowledging a possible association between ALCL and breast implants. 71 Although the FDA did not confirm breast implants as the cause, it did report that women with implants have a very small but increased risk of developing ALCL. The American Society of Plastic Surgeons and the FDA are currently collaborating to establish a registry of ALCL cases among women with breast implants to allow for more complete analysis. 71 The FDA has advised health care providers and implant manufacturers to report confirmed cases of iALCL through "MedWatch: The FDA Safety Information and Adverse Event Reporting Program." Reports may be filed online at https:// www.accessdata.fda.gov/scripts/medwatch/medwatchonline.htm or by telephoning 1-800-332-1088. 71 A summary of the FDA's key findings and recommendations appears in Table 4 . Implant characteristics There is currently not enough information available to link specific type, surface, or indication for implants to the development of iALCL. Etiology Due to the low incidence, it is not possible to confirm that implants are the etiologic agent of iALCL.
Diagnosis
Health care providers should consider the diagnosis of iALCL for patients presenting with a late-onset, recurrent, periprosthetic fluid collection in the breast.
Management
Seroma aspirate and adjacent samples of the implant capsule should be sent for pathologic evaluation. Appropriate evaluation includes Wright Giemsa stain and cell block immunohistochemistry for cluster differentiation and ALK.
Reporting
All confirmed cases of iALCL should be reported to the US Food and Drug Administration's registry.
Treatment
Due to the low incidence of this disease, there is not a defined consensus for treatment.
Abbreviations: ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; iALCL, breast implant-associated anaplastic large cell lymphoma.
ConCLuSionS
To our knowledge, this review of 63 known cases of iALCL is the largest to date. Many questions remain about the nature of this rare disease. Health care workers and plastic surgeons will need to collaborate fully to develop definitive guidelines for the treatment, management, and prevention of this disease.
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